Libtayo (cemiplimab-rwlc) / Regeneron 
Welcome,         Profile    Billing    Logout  
 1 Disease   67 Trials   67 Trials   1555 News 


«12...1112131415161718192021...3940»
  • ||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Libtayo (cemiplimab) / Regeneron
    Journal:  Current Management of Basal Cell Carcinoma (Pubmed Central) -  Dec 16, 2022   
    With long-termhedgehog therapy, an adapted dosage scheme can avoid discontinuation of therapy due to side effects. The therapeutic potential of the PD-1 inhibitor cemiplimab can also be used with the side effect profile known from other types of skin cancer.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron
    Use of checkpoint inhibitors in pulmonary transplanted patients: Strasbourg experience (Display area) -  Dec 14, 2022 - Abstract #CPLF2023CPLF_193;    
    Despite the cemiplimab stop and the realization of a bolus of corticosteroids, the patient died in early June 2020...The main post-graf complications were a chronic rejection of the obliterating bronchiolitis, treated by azithromycin and photophérèse extracorporelle, then in 2017, a melanoma of Dubreuilh judgal left, mutated NF1, treated by surgical resection with healthy margins...The IS treatment of the patient included tacrolimus, prednisolone and mycophenolic acid, replaced by Everolimus...In the absence of current consensus, it seems imperative to discuss each file on a case -by -case basis. Other studies will be necessary to improve our knowledge on this subject.
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron
    Trial completion, Trial completion date, Trial primary completion date:  TOSCA: Comparative Efficacy of Cemiplimab to Historical Standard of Care in France (clinicaltrials.gov) -  Dec 13, 2022   
    P=N/A,  N=305, Completed, 
    Clinical trial information: NCT04626635. Active, not recruiting --> Completed | Trial completion date: Mar 2023 --> Sep 2022 | Trial primary completion date: Mar 2023 --> Sep 2022
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Trial completion:  A Study of Isatuximab-based Therapy in Participants With Lymphoma (clinicaltrials.gov) -  Dec 13, 2022   
    P1/2,  N=58, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Mar 2023 --> Sep 2022 | Trial primary completion date: Mar 2023 --> Sep 2022 Active, not recruiting --> Completed
  • ||||||||||  Libtayo (cemiplimab) / Regeneron
    Journal:  Cutaneous squamous cell carcinoma of the head and neck (Pubmed Central) -  Dec 2, 2022   
    Therefore, imaging, surgical therapy and follow-up intervals should be based on risk factors. This allows early detection of metastases or local recurrences and improves the prognosis.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron
    Journal:  Multimodality Therapy for Locally Advanced Cutaneous Squamous Cell Carcinoma (Pubmed Central) -  Nov 18, 2022   
    With the approval of the monoclonal antibody cemiplimab, which targets the programmed death-1 receptor (PD-1), the prognosis of affected patients has improved significantly, and in some cases sustained complete remission can be achieved.This case report describes a multimorbid, 81-year-old patient who was initially treated with cemiplimab due to extensive squamous cell carcinoma frontoparietal with cranial dome infiltration and invasion intracranially...At 6 months postoperatively, there was no evidence of local recurrence or metastasis.This case exemplifies a patient who, despite his advanced age and co-morbidities, benefited from initiated immune checkpoint inhibitor therapy. Furthermore, it shows the relevance of an interdisciplinary/multimodal therapy regime in the management of this tumor entity, which is increasing in incidence.
  • ||||||||||  Libtayo (cemiplimab) / Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
    Review, Journal:  Recent Advances in Immunotherapy for Patients with Head and Neck Cutaneous Squamous Cell Carcinoma. (Pubmed Central) -  Nov 16, 2022   
    Immunotherapy has dramatically improved outcomes in this patient population due to its favorable side effect profile, durable treatment response, and improved overall outcomes. In this review, an overview of the recent advances of immunotherapy in the management of CSCC in the anatomical head and neck region is provided, with a focus on advanced presentations.